Futura Medical plc (FAMDF)

0.5512 -0.0588 (-9.64%) As of 09:40AM EDT. Market open.

Futura Medical plc

Surrey Technology Centre
40 Occam Road
Guildford GU2 7YG
United Kingdom
44 14 8368 5670
https://www.futuramedical.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 12

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James Henry Barder	CEO & Exec. Director	491.79k	N/A	1960
Ms. Angela Hildreth	COO, Fin. Director, Company Sec. & Exec. Director	384.92k	N/A	N/A
Mr. Kenneth William James	Head of R&D & Exec. Director	352.47k	N/A	1953
Dr. William Duncan Potter	Chief Scientific Officer & Adviser to the Board	N/A	N/A	1948
Graham Smith	Head of Alliance Partnerships & Supply	N/A	N/A	N/A
Kevin Langridge	Head of Quality	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

Corporate governance

Futura Medical plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.